Trial Profile
A pivotal study of SU011248 [sunitinib] in the treatment of patients with cytokine-refractory metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer; Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 22 Oct 2015 Post hoc pooled analysis results published in the British Journal of Cancer
- 05 Mar 2010 Results of a subgroup analysis in patients with papillary RCC were presented at ASCO 2010 Genitourinary Cancers Symposium
- 08 Apr 2009 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.